trials
Zenas Biotech Secures $200 Million for Advancing Obexelimab in Pivotal Immunology Trials
Zenas Biotech, obexelimab, immunology trials, funding, biotechnology, drug development, autoimmune diseases, B-cell-directed therapy.
Eli Lilly’s Zepbound Shows Promising Results in Reducing Sleep Apnea Severity in Pivotal Trials
Eli Lilly, Zepbound, Sleep Apnea, Obstructive Sleep Apnea (OSA), Pivotal Trials, Obesity, GLP-1 Receptor Agonist, Tirzepatide, CPAP, Weight Loss